Anzeige
Mehr »
Mittwoch, 18.06.2025 - Börsentäglich über 12.000 News
Sommerexploration startet - direkt neben Ramp Metals!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
354 Leser
Artikel bewerten:
(2)

Orion Oyj: Change in Orion Group Executive Management Board as of February 1st, 2024 - Julia Macharey appointed Senior Vice President, People & Culture

ORION CORPORATION
STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS
22 August 2023 at 14.00 EEST

Change in Orion Group Executive Management Board as of February 1st, 2024 - Julia Macharey appointed Senior Vice President, People & Culture

Ms. Julia Macharey has been appointed Senior Vice President of Orion Group's new People & Culture group-level function and member of the Executive Management Board of Orion Group as of February 1st 2024. She will report to President & CEO Liisa Hurme. She currently holds the position of Senior Vice President, Human Resources and Operational Development at Valmet and is a member of the Valmet Executive Team. Julia Macharey holds a Master of Science degree in Economics and a Bachelor of Arts degree.

"With this appointment, I wanted to support the implementation of our global growth strategy and to strengthen the building of Orion's corporate culture. Based on her previous experience and track record, Julia Macharey will bring both global organizational and business perspective to Orion," says Orion's President & CEO Liisa Hurme.

"I am very excited about the opportunity of joining a team of world-class experts who endeavor to improve well-being through life-saving and life-improving medicines and treatments. Orion's people-oriented culture based on working together to create high-quality products is only one of the many reasons why I am looking forward to supporting Orion on its growth path," says Julia Macharey about the appointment.

The new People & Culture function will focus on developing Orion's professionals, capabilities and company culture and supporting growth, and Human Resources will be at the heart of this new group-level function as of February 1st.

"Orion's organisation has seen significant geographical expansion in recent years, and we want to continue developing our people and culture in a global and systematic way. I am excited about the new opportunities in this and I warmly welcome Julia to Orion and to our management team," says Liisa Hurme.

ANNEX: CV of Julia Macharey

Julia Macharey
Born 1977
Finnish citizen


Education:

Master of Science in Economics, University of Jyväskylä, 2000
Bachelor of Arts (Intercultural Communication), University of Jyväskylä, 1999

Career:

Valmet

2019- Senior Vice President, Human Resources and Operational Development
2014-2019 Senior Vice President, Human Resources

Metso Corporation, Metso Paper
2012-2013 Senior Vice President, Human Resources of Metso Pulp, Paper and Power segment

Pöyry Plc
2007-2012 Vice President, Human Resources of Industry Business Group


Nokia Corporation
2006-2007 Senior Manager, Business HR of Manufacturing Solutions
2004-2006 Senior Manager, Business HR of Sourcing and Procurement

SCA Hygiene Products Ltd and GmbH
2000-2004 Human Resources Manager and various HR management responsibilities

Attachment:

  • Julia Macharey (https://www.globenewswire.com/NewsRoom/AttachmentNg/2bb1fdd3-1ead-4a2c-8576-00f275e80543) (image)

Orion Corporation

Liisa Hurme

President and CEO
Olli Huotari

SVP, Corporate Functions


Contact person:
Liisa Hurme, President and CEO
tel. +358 50 966 2874, liisa.hurme@orion.fi

Contact personforthe media:
Terhi Ormio, VP, Communications
tel. + 358 50 966 4646, terhi.ormio@orion.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Attachment

  • Julia Macharey (https://ml-eu.globenewswire.com/Resource/Download/2bb1fdd3-1ead-4a2c-8576-00f275e80543)

© 2023 GlobeNewswire (Europe)
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.